Anbio Biotechnology (NNNN): Total Liabilities
$87.8K
As of 2025-12-31
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $87.8K | -94.9% | 2026-04-07, Balance as of period end |
| 2024-12-31 | $1.73M | +74.2% | 2026-04-07, Balance as of period end |
| 2023-12-31 | $993.1K | n/a | 2025-04-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Anbio Biotechnology (NNNN) | 2025-12-31 | $87.8K | -94.9% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $12.39M | +53.8% |
| Biomerica Inc (BMRA) | 2026-05-31 | $4.13M | +124.4% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $57.22M | +20.8% |
| Immucell Corp (ICCC) | 2025-12-31 | $15.48M | -12.0% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $34.81M | -4.3% |
| Volitionrx Ltd (VNRX) | 2025-12-31 | $42.49M | +19.7% |
| Celldex Therapeutics, Inc. (CLDX) | 2025-12-31 | $55.82M | +23.1% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $170.73M | -46.5% |
Compare NNNN, AWHL, BMRA, IMDX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗